{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:51:04Z","timestamp":1790970664578,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2007,8,16]],"date-time":"2007-08-16T00:00:00Z","timestamp":1187222400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurochem Res"],"published-print":{"date-parts":[[2007,9,17]]},"DOI":"10.1007\/s11064-007-9351-8","type":"journal-article","created":{"date-parts":[[2007,8,14]],"date-time":"2007-08-14T22:56:29Z","timestamp":1187132189000},"page":"1694-1699","source":"Crossref","is-referenced-by-count":47,"title":["Rasagiline Promotes Regeneration of Substantia Nigra Dopaminergic Neurons in Post-MPTP-induced Parkinsonism via Activation of Tyrosine Kinase Receptor Signaling Pathway"],"prefix":"10.1007","volume":"32","author":[{"given":"Silvia A.","family":"Mandel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotam","family":"Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamar","family":"Amit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,8,16]]},"reference":[{"key":"9351_CR1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1136\/jnnp.64.3.314","volume":"64","author":"PK Morrish","year":"1998","unstructured":"Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson\u2019s disease with [18F]dopa PET. J Neurol Neurosurg Psychiatr 64:314\u2013319","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"9351_CR2","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1212\/01.WNL.0000058760.13152.1A","volume":"60","author":"BM Ravina","year":"2003","unstructured":"Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, Marler JR (2003) Neuroprotective agents for clinical trials in Parkinson\u2019s disease: a systematic assessment. Neurology 60:1234\u20131240","journal-title":"Neurology"},{"key":"9351_CR3","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","volume":"132","author":"MBH Youdim","year":"2001","unstructured":"Youdim MBH, Gross A, Finberg JPM (2001) Rasagiline [N-propargyl-1R(+)-aminoindant], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132:500\u2013506","journal-title":"Br J Pharmacol"},{"key":"9351_CR4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","volume":"365","author":"O Rascol","year":"2005","unstructured":"Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947\u2013954","journal-title":"Lancet"},{"key":"9351_CR5","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1001\/archneur.61.4.561","volume":"61","author":"Parkinson Study Group","year":"2004","unstructured":"Parkinson Study Group (2004) A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61:561\u2013566","journal-title":"Arch Neurol"},{"key":"9351_CR6","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/mds.20764","volume":"21","author":"KM Biglan","year":"2006","unstructured":"Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn S, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I (2006) Rasagiline improves quality of life in patients with early Parkinson\u2019s disease. Mov Disord 21:616\u2013623","journal-title":"Mov Disord"},{"key":"9351_CR7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","volume":"23","author":"JM Rabey","year":"2000","unstructured":"Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G (2000) Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson\u2019s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 23:324\u2013330","journal-title":"Clin Neuropharmacol"},{"key":"9351_CR8","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1527-3458.2005.tb00269.x","volume":"11","author":"F Blandini","year":"2005","unstructured":"Blandini F (2005) Neuroprotection by rasagiline: a new therapeutic approach to Parkinson\u2019s disease? CNS Drug Rev 11:183\u2013194","journal-title":"CNS Drug Rev"},{"key":"9351_CR9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.2001.tb03656.x","volume":"939","author":"MB Youdim","year":"2001","unstructured":"Youdim MB, Wadia A, Tatton W, Weinstock M (2001) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939:450\u2013458","journal-title":"Ann N Y Acad Sci"},{"key":"9351_CR10","doi-asserted-by":"crossref","unstructured":"Maruyama W, Akao Y, Youdim MBH, Naoi M (2000) Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm 60(Suppl):171\u2013186","DOI":"10.1007\/978-3-7091-6301-6_11"},{"key":"9351_CR11","first-page":"495","volume":"80","author":"JP Finberg","year":"1999","unstructured":"Finberg JP, Lamensdorf I, Weinstock M, Schwartz M, Youdim MBH (1999) Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 80:495\u2013499","journal-title":"Adv Neurol"},{"key":"9351_CR12","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1471-4159.2002.01047.x","volume":"82","author":"Y Akao","year":"2002","unstructured":"Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MB, Tsujimoto Y, Naoi M (2002) Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82:913\u2013923","journal-title":"J Neurochem"},{"key":"9351_CR13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/bies.10378","volume":"26","author":"R Tabakman","year":"2004","unstructured":"Tabakman R, Lecht S, Lazarovici P (2004) Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson\u2019s disease? Bioessays 26:80\u201390","journal-title":"Bioessays"},{"key":"9351_CR14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0014-2999(85)90168-2","volume":"116","author":"RE Heikkila","year":"1985","unstructured":"Heikkila RE, Duvoisin RC, Finberg JP, Youdim MBH (1985) Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur J Pharmacol 116:313\u2013317","journal-title":"Eur J Pharmacol"},{"key":"9351_CR15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.expneurol.2004.03.005","volume":"187","author":"F Blandini","year":"2004","unstructured":"Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G (2004) Neuroprotective effect of rasagiline in a rodent model of Parkinson\u2019s disease. Exp Neurol 187:455\u2013459","journal-title":"Exp Neurol"},{"key":"9351_CR16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s007020050182","volume":"106","author":"Z Speiser","year":"1999","unstructured":"Speiser Z, Mayk A, Eliash S, Cohen S (1999) Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm 106:593\u2013606","journal-title":"J Neural Transm"},{"key":"9351_CR17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(98)00929-7","volume":"366","author":"W Huang","year":"1999","unstructured":"Huang W, Chen Y, Shohami E, Weinstock M (1999) Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 366:127\u2013135","journal-title":"Eur J Pharmacol"},{"key":"9351_CR18","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1096\/fj.05-3794fje","volume":"19","author":"O Bar-Am","year":"2005","unstructured":"Bar-Am O, Weinreb O, Amit T, Youdim MBH (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19:1899\u20131901","journal-title":"FASEB J"},{"key":"9351_CR19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.nbd.2006.07.020","volume":"25","author":"Y Sagi","year":"2007","unstructured":"Sagi Y, Mandel S, Amit T, Youdim MB (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25:35\u201344","journal-title":"Neurobiol Dis"},{"key":"9351_CR20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/311467a0","volume":"311","author":"RE Heikkila","year":"1984","unstructured":"Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311:467\u2013469","journal-title":"Nature"},{"key":"9351_CR21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/jnr.20350","volume":"79","author":"MBH Youdim","year":"2005","unstructured":"Youdim MBH, Bar-Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, Amit T (2005) Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res 79:172\u2013179","journal-title":"J Neurosci Res"},{"key":"9351_CR22","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1096\/fj.04-1916fje","volume":"18","author":"O Weinreb","year":"2004","unstructured":"Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, Youdim MBH (2004) Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18:1471\u20131473","journal-title":"FASEB J"},{"key":"9351_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00702-005-0299-z","volume":"113","author":"H Yi","year":"2005","unstructured":"Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MBH, Naoi M (2005) N-propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113:21\u201332","journal-title":"J Neural Transm"},{"key":"9351_CR24","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neuint.2003.08.005","volume":"44","author":"W Maruyama","year":"2004","unstructured":"Maruyama W, Nitta A, Shamoto-Nagai M, Hirata Y, Akao Y, Youdim MB H, Furukawa S, Nabeshima T, Naoi M (2004) N-propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor. Neurochem Int 44:393\u2013400","journal-title":"Neurochem Int"},{"key":"9351_CR25","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1046\/j.1471-4159.2001.00490.x","volume":"78","author":"Y Levites","year":"2001","unstructured":"Levites Y, Weinreb O, Maor G, Youdim MBH, Mandel S (2001) Green tea polyphenol (-)- Epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78:1073\u20131082","journal-title":"J Neurochem"},{"key":"9351_CR26","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1083\/jcb.146.5.955","volume":"146","author":"AR Vaillant","year":"1999","unstructured":"Vaillant AR, Mazzoni I, Tudan C, Boudreau M, Kaplan DR, Miller FD (1999) Depolarization and neurotrophins converge on the phosphatidylinositol 3-kinase-Akt pathway to synergistically regulate neuronal survival. J Cell Biol 146:955\u2013966","journal-title":"J Cell Biol"},{"key":"9351_CR27","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/MCB.22.3.916-926.2001","volume":"22","author":"Y Wang","year":"2002","unstructured":"Wang Y, Waldron RT, Dhaka A, Patel A, Riley MM, Rozengurt E, Colicelli J (2002) The RAS effector RIN1 directly competes with RAF and is regulated by 14-3-3 proteins. Mol Cell Biol 22:916\u2013926","journal-title":"Mol Cell Biol"},{"key":"9351_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(96)00593-6","volume":"315","author":"I Semkova","year":"1996","unstructured":"Semkova I, Wolz P, Schilling M, Krieglstein J (1996) Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage. Eur J Pharmacol 315:19\u201330","journal-title":"Eur J Pharmacol"},{"key":"9351_CR29","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1124\/jpet.301.2.753","volume":"301","author":"WG Tatton","year":"2002","unstructured":"Tatton WG, Chalmers-Redman RM, Ju WJ, Mammen M, Carlile GW, Pong AW, Tatton NA (2002) Propargylamines induce antiapoptotic new protein synthesis in serum- and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301:753\u2013764","journal-title":"J Pharmacol Exp Ther"},{"key":"9351_CR30","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/j.1471-4159.2005.03474.x","volume":"95","author":"F Liu","year":"2005","unstructured":"Liu F, Gong X, Zhang G, Marquis K, Reinhart P, Andree TH (2005) The inhibition of glycogen synthase kinase 3beta by a metabotropic glutamate receptor 5 mediated pathway confers neuroprotection to Abeta peptides. J Neurochem 95:1363\u20131372","journal-title":"J Neurochem"},{"key":"9351_CR31","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1124\/mol.105.018671","volume":"69","author":"M D\u2019Astous","year":"2006","unstructured":"D\u2019Astous M, Mendez P, Morissette M, Garcia-Segura LM, Di Paolo T (2006) Implication of the phosphatidylinositol-3 kinase\/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol Pharmacol 69:1492\u20131498","journal-title":"Mol Pharmacol"},{"key":"9351_CR32","doi-asserted-by":"crossref","first-page":"5731","DOI":"10.1242\/jcs.01505","volume":"117","author":"G Castelo-Branco","year":"2004","unstructured":"Castelo-Branco G, Rawal N, Arenas E (2004) GSK-3beta inhibition\/beta-catenin stabilization in ventral midbrain precursors increases differentiation into dopamine neurons. J Cell Sci 117:5731\u20135737","journal-title":"J Cell Sci"},{"key":"9351_CR33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.tips.2004.07.006","volume":"25","author":"L Meijer","year":"2004","unstructured":"Meijer L, Flajolet M, Greengard P (2004) Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol Sci 25:471\u2013480","journal-title":"Trends Pharmacol Sci"},{"key":"9351_CR34","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00702-005-0299-z","volume":"113","author":"H Yi","year":"2006","unstructured":"Yi H, Maruyama W, Akao Y, Takahashi T, Iwasa K, Youdim MB, Naoi M (2006) N-propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J Neural Transm 113:21\u201332","journal-title":"J Neural Transm"},{"key":"9351_CR35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0304-3940(99)00463-2","volume":"270","author":"M Mogi","year":"1999","unstructured":"Mogi M, Togari A, Kondo T, Mizuno Y, Komure O, Kuno S, Ichinose H, Nagatsu T (1999) Brain-derived growth factor and nerve growth factor concentrations are decreased in the substantia nigra in Parkinson\u2019s disease. Neurosci Lett 270:45\u201348","journal-title":"Neurosci Lett"},{"key":"9351_CR36","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1097\/00001756-199807130-00039","volume":"9","author":"I Date","year":"1998","unstructured":"Date I, Aoi M, Tomita S, Collins F, Ohmoto T (1998) GDNF administration induces recovery of the nigrostriatal dopaminergic system both in young and aged parkinsonian mice. Neuroreport 9:2365\u20132369","journal-title":"Neuroreport"},{"key":"9351_CR37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-8993(97)01495-9","volume":"789","author":"PA Lapchak","year":"1998","unstructured":"Lapchak PA, Araujo DM, Hilt DC, Jiao S, Collin F, Miyoshi Y, Yi A, Zhang Z, Gash DM (1998) Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection. Brain Res 789:9\u201322","journal-title":"Brain Res"},{"key":"9351_CR38","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/373335a0","volume":"373","author":"A Tomac","year":"1995","unstructured":"Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, Olson L (1995) Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335\u2013339","journal-title":"Nature"},{"key":"9351_CR39","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1006\/bbrc.1997.7183","volume":"238","author":"H Kojima","year":"1997","unstructured":"Kojima H, Abiru Y, Sakajiri K, Watabe K, Ohishi N, Takamori M, Hatanaka H, Yagi K (1997) Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem Biophys Res Commun 238:569\u2013573","journal-title":"Biochem Biophys Res Commun"},{"key":"9351_CR40","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.gt.3301682","volume":"9","author":"L Wang","year":"2002","unstructured":"Wang L, Muramatsu S, Lu Y, Ikeguchi K, Fujimoto K, Okada T, Mizukami H, Hanazono Y, Kume A, Urano F, Ichinose H, Nagatsu T, Nakano I, Ozawa K (2002) Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson\u2019s disease. Gene Ther 9:381\u2013389","journal-title":"Gene Ther"},{"key":"9351_CR41","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/380252a0","volume":"380","author":"DM Gash","year":"1996","unstructured":"Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt GA (1996) Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252\u2013255","journal-title":"Nature"},{"key":"9351_CR42","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2165\/00023210-200519090-00001","volume":"19","author":"SS Wu","year":"2005","unstructured":"Wu SS, Frucht SJ (2005) Treatment of Parkinson\u2019s disease: what\u2019s on the horizon? CNS Drugs 19:723\u2013743","journal-title":"CNS Drugs"},{"key":"9351_CR43","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm0705-703","volume":"11","author":"S Love","year":"2005","unstructured":"Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS (2005) Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11:703\u2013704","journal-title":"Nat Med"},{"key":"9351_CR44","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1096\/fj.03-0078fje","volume":"17","author":"M Yogev-Falach","year":"2003","unstructured":"Yogev-Falach M, Amit T, Bar-AM O, Youdim MBH (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J 17:2325\u20132327","journal-title":"FASEB J"},{"key":"9351_CR45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1196\/annals.1344.030","volume":"1053","author":"O Weinreb","year":"2005","unstructured":"Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MBH (2005) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci 1053:348\u2013355","journal-title":"Ann N Y Acad Sci"},{"key":"9351_CR46","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1111\/j.1471-4159.2006.04141.x","volume":"99","author":"CJ Schyf Van der","year":"2006","unstructured":"Van der Schyf CJ, Geldenhuys WJ, Youdim MB (2006) Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J Neurochem 99:1033\u20131048","journal-title":"J Neurochem"}],"container-title":["Neurochemical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-007-9351-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11064-007-9351-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11064-007-9351-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:34:31Z","timestamp":1559363671000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11064-007-9351-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,16]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2007,9,17]]}},"alternative-id":["9351"],"URL":"https:\/\/doi.org\/10.1007\/s11064-007-9351-8","relation":{},"ISSN":["0364-3190","1573-6903"],"issn-type":[{"value":"0364-3190","type":"print"},{"value":"1573-6903","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,16]]}}}